Polyrizon Secures $17 Million Funding and Advances Allergy Hydrogel Trials

Introduction

Polyrizon Ltd (NASDAQ: PLRZ) is a development-stage biotechnology company based in Ra’anana, Israel, specializing in intranasal medical device hydrogels. Its proprietary Capture and Contain™ (C&C) hydrogel technology forms a thin barrier in the nasal cavity, designed to block viruses and allergens from contacting the nasal epithelium. The company is also developing a preclinical platform, Trap and Target™ (T&T), for the intranasal delivery of active pharmaceutical ingredients.

Corporate Structure and Leadership

Founded in 2020, Polyrizon operates with a team of fewer than ten employees. The executive leadership includes Tomer Izraeli (B.Sc, MBA), Founder & Chief Executive Officer, who has over 18 years of experience in medical device and pharmaceutical development; Nir Ben Yosef (CPA, B.A), Chief Financial Officer; Daphna Avital (MA), Chief People Officer; Dr. Tidhar Turgeman, Chief Technology Officer; Yuliya Yutkevich, Quality Assurance & Regulatory Affairs Director; and Dr. Eyal S. Ron, Chief Scientific Officer. The Scientific Advisory Board comprises Prof. Avi Schroeder, Prof. Smadar Cohen, Prof. Fabio Sonvico, and Prof. Nancy Agmon-Levin. The Board of Directors includes independent members Asaf Itzhaik, Liat Sidi, Yehonatan Zalman Vinokur, and Liron Carmel.

Hydrogel technology by Dan Cristian Pădureț

Recent Developments

On March 31, 2025, Polyrizon announced a private placement raising approximately $17.0 million through the sale of 35.4 million Ordinary Units at $0.48 per unit, which includes investor warrants exercisable at $1.20. The net proceeds are intended for general corporate purposes and working capital.

Effective May 27, 2025, the company implemented a 1-for-250 reverse share split, reducing its share count from approximately 1.33 billion to 5.33 million ordinary shares while retaining its authorized capital. Following a Nasdaq hearings panel on July 15, 2025, Polyrizon retained its listing on the Nasdaq Capital Market, indicating compliance with exchange requirements.

Polyrizon entered a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S to supply clinical trial material for PL-14, its allergy blocker hydrogel, in preparation for a Phase 1 clinical trial scheduled for 2025.

On July 22, 2025, the company reported successful intranasal delivery of PL-14 in a recent study, which is a step toward clinical development of its allergy treatment.

Financial and Strategic Analysis

As of July 22, 2025, PLRZ shares closed at $1.7494, up 92.71 percent on a volume of 19.08 million shares. Data from TipRanks indicates an average daily trading volume of approximately 20.76 million shares and a market capitalization near $4.53 million. The private placement is expected to strengthen the balance sheet, extending operational capacity through ongoing research and development and regulatory efforts. The reverse split aims to improve per-share metrics, while retention of the Nasdaq listing supports future capital raising efforts.

Strategically, Polyrizon focuses on advancing C&C hydrogel applications, initially for allergy protection and later as a platform for intranasal drug delivery. The results from the PL-14 study and the upcoming clinical trial are seen as significant developments. Successful outcomes in these programs could support the validation of the “biological mask” concept and establish a foundation for future partnerships or licensing agreements.

Market Position and Industry Context

Within the biotechnology sector, intranasal delivery systems are increasingly recognized for their potential in non-invasive administration of therapeutics and prophylactics. Polyrizon competes with established pharmaceutical firms and smaller biotech startups that are exploring similar nasal formulations. Its hydrogel platform aims to address unmet needs in allergy prevention and drug delivery. The company's early-stage status and small workforce contrast with larger competitors, highlighting the importance of efficient capital use and strategic partnerships with contract development and manufacturing organizations (CDMOs) and research institutions.

tl;dr

On March 31, 2025, Polyrizon raised $17 million in a private placement. The company executed a 1-for-250 reverse share split on May 27, 2025, and maintained its Nasdaq listing following a July 15 hearing. A manufacturing agreement with Eurofins CDMO secures PL-14 clinical trial material ahead of a planned Phase 1 study in 2025. On July 22, 2025, Polyrizon announced successful intranasal delivery of its allergy blocker, PL-14. Recent funding and trial preparations position the company to advance its hydrogel-based nasal spray platform toward regulatory milestones in the coming months.